ImmunoBrain Checkpoint Inc., a clinical stage biopharmaceutical company developing disease-modifying immune therapies to combat neurodegenerative diseases, has appointed Dr. Sanjay Keswani, MD, BSc, FRCP, as its president and chief executive officer.
 
Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, UK. Sanjay has served as Senior Vice President of R&D at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. 
 
Sanjay has been instrumental in the development of several approved medicines, including Risdiplam, Emgality, Faricimab, Cymbalta, Aimovig and Deucravacitnib. 
 
“As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain,” said Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain. “We are confident that Dr. Keswani’s passion for developing effective solutions for patients, as well as his successful track record of building high-performing teams across a diverse range of biopharma companies, will result in transformative growth at ImmunoBrain and improved treatment and outcomes for individuals living with neurological conditions.”